A South African developed injectable oil emulsion bacterin against infectious coryza, to ensure fowls produce on expectation.

An oil-emulsion of inactivated *Avibacterium paragallinarum* containing at least $1 \times 10^8$ colony forming units per dose of both serotypes A and C.

### About us

Deltamune, with a history dating back to 1977, is a Gauteng based South African company focusing on veterinary public health. Inactivated vaccines focusing on South African strains have been produced since 1980, and the development of ELISA tests for various poultry diseases commenced in 1985. At Deltamune we support our customers to achieve their production goals, backed by state of the art vaccines research and development, manufacture of biological products, and supported by an ISO 17025 (SANAS V.0007) accredited and Department of Agriculture, Forestry and Fisheries (DAFF) approved test laboratory.

### Product Range and Capabilities

<table>
<thead>
<tr>
<th>Disease</th>
<th>AI</th>
<th>E.coli</th>
<th>E.coli O157</th>
<th>IBD</th>
<th>IB</th>
<th>IBD</th>
<th>IN</th>
<th>OR</th>
<th>PM</th>
<th>SE</th>
<th>SG</th>
<th>SI</th>
<th>SM</th>
<th>ST</th>
</tr>
</thead>
<tbody>
<tr>
<td>AVIVAC® AI</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>AVIVAC® COR/EDS</td>
<td></td>
<td>X</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>AVIVAC® CORYZA</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>AVIVAC® ND</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>AVIVAC® SE</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>STRUVAC ND PLUS</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Autogenous vaccine solutions provided through veterinarians include:

- X
- X
- X
- X
- X
- X
- X
- X
- X

Vaccine support products:

- X
- X
- X
- X
- X
- X
- X
- X
- X

Contact us for solutions to your vaccination and laboratory needs

Email: info@deltamune.co.za  Website: www.deltamune.co.za

Telephone: +27 (0)12 664 5730  Fax: +27 (0)12 664 5149

Registration holder: DELTAMUNE (PTY) LTD Reg No 1994/005981/07

AVIVAC® is distributed by: Immuno-Vet Services CC (Reg. No. 1988/025418/23)

Telephone: +27 (0)11 699-6240  Fax: +27 (0)11 462 0869

Website: www.immunovet.co.za  Email: info@immunovet.co.za
What is Coryza?

Infectious Coryza is an acute, highly contagious disease affecting the upper respiratory tract mainly of adult fowls. The causative bacterium is Avibacterium (Haemophilus) paragallinarum. The main source of infection is clinically affected and carrier birds. The bacterium can be transmitted via the drinking water or feed contaminated by nasal discharge, by aerosols over short distances, via the drinking water or feed contaminated by carrier birds. The bacterium can be transmitted through a flock. Most susceptible birds will contract the disease but unless complicated by secondary infections the mortality remains low. The most prominent clinical signs are seromucoid nasal and ocular discharges and facial oedema. In severe cases marked conjunctivitis with closed eyes, swollen wattles and difficult breathing can be seen. In layers and breeders a drop in egg production of 10% to 40% can be expected and an increase in the number of culls.Recovered birds remain carriers of the bacterium. In addition to effective immunisation with a suitable vaccine containing the relevant strains for a certain area, it is preferable to have all-in-all-out production systems and to apply strict biosecurity to prevent outbreaks. Antimicrobial treatment is of limited value.

Development of this vaccine was done according to GLP guidelines, and animal studies performed following GCP guidelines. Manufacturing of the vaccine is conducted in a facility that adheres to European GMP guidelines. Sterility testing is performed in the Deltamune ISO 17025 accredited laboratory (SANAS V.0007: VAC-QCD-ME-019 method).

AVIVAC® CORYZA provides very high efficacy and rapid bacterial clearance from sinuses as shown in comparative challenge tests with Serotype A*

AVIVAC® CORYZA reduces potential production losses up to 15% more effective than other commercial vaccines

AVIVAC® CORYZA provides very high efficacy and rapid bacterial clearance from sinuses as shown in comparative challenge tests with Serotype A*

AVIVAC® CORYZA provides effective cross immunity against multiple serotypes*

AVIVAC® CORYZA administration monitoring can be performed with ELISA tests

AVIVAC® CORYZA tissue reaction is acceptable compared to other vaccines*

Advantages of using AVIVAC® CORYZA

- Local strains increases efficacy
- Oil adjuvanted vaccine ensures high immune response and long duration of immunity
- Minimises egg production losses in the event of an outbreak
- Ease of application through intramuscular route
- Antigen component selected to have the most immunogenic effect
- World-class technical and laboratory support for the product provided by Deltamune

AVIVAC® CORYZA is indicated for preventive immunisation of healthy fowls against infectious Coryza. The immunity induced should reach a maximum 3 weeks after the administration of the vaccine and should last for 30-40 weeks from vaccination, giving effective protection for the productive life of the fowls. Serotypes included: A, C3 - both locally isolated strains.

Recommended dosage

For breeders and replacement pullets between 6-10 weeks of age: A dose of 0.5 ml injected intramuscularly into the breast muscle.

Alternative dosage

For breeders and replacement pullets between 13-16 weeks of age: One dose of 1.0 ml injected intramuscularly.